Element Biosciences IPO
Element Biosciences develops next-generation DNA sequencing platforms and chemistry solutions for genomics research and clinical applications. The company's AVITI sequencing system aims to provide high-quality, cost-effective sequencing with improved accuracy and workflow efficiency. Investors are interested in Element's potential to compete in the multi-billion dollar genomics market dominated by Illumina.
Key Facts
| Industry | Biotechnology |
| Founded | 2017 |
| Headquarters | San Diego, CA |
| Employees | ~300 |
| Website | elementbiosciences.com |
| Funding | Series C raised $276M in 2021. Total raised: ~$400M |
About Element Biosciences
Element Biosciences is developing next-generation DNA sequencing technology that aims to make genomic analysis more accessible and cost-effective. The company's flagship product, the AVITI System, uses a novel sequencing-by-synthesis chemistry and engineering approach designed to deliver high-quality sequencing data at a lower cost per gigabase than existing solutions.
Founded by former Illumina executives, Element Biosciences is positioned to challenge the dominant players in the DNA sequencing market by offering improved performance, simplified workflows, and reduced operational complexity. The company's technology platform focuses on applications in clinical diagnostics, pharmaceutical research, and academic genomics, with particular emphasis on making whole genome sequencing more economically viable for routine clinical use.
IPO Status
Element Biosciences has not announced any plans for an initial public offering. The company has raised significant venture funding, including a $276 million Series C round in 2021, but has kept its IPO timeline private. As a growing player in the competitive DNA sequencing market, Element would likely need to demonstrate strong commercial traction with its AVITI platform and establish market share before considering going public. The genomics sector has seen mixed IPO performance in recent years, which may influence the company's timing decisions.
Competitors
Frequently Asked Questions
Does Element Biosciences have a stock?
No, Element Biosciences has not had an IPO and remains a private company. The genomics company has raised venture funding but has not announced plans to go public.
When is the Element Biosciences IPO date?
Element Biosciences has not announced an IPO date or timeline. The company appears focused on scaling its sequencing platform commercially before considering public markets.
How can I buy Element Biosciences stock?
You cannot currently buy Element Biosciences stock as it remains privately held. Once the company goes public, shares would be available through brokers on major exchanges.
Stay Updated on the Element Biosciences IPO
Get real-time alerts when Element Biosciences files for an IPO, prices shares, or begins trading.
Get IPO Alerts